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Abstract
The SLC30A8 gene codes for a pancreatic beta-cell-expressed zinc transporter, ZnT8. A polymorphism in the SLC30A8 gene is
associated with susceptibility to type 2 diabetes, although the molecular mechanism through which this phenotype is
manifest is incompletely understood. Such polymorphisms may exert their effect via impacting expression level of the gene
product. We used an shRNA-mediated approach to reproducibly downregulate ZnT8 mRNA expression by .90% in the INS-
1 pancreatic beta cell line. The ZnT8-downregulated cells exhibited diminished uptake of exogenous zinc, as determined
using the zinc-sensitive reporter dye, zinquin. ZnT8-downregulated cells showed reduced insulin content and decreased
insulin secretion (expressed as percent of total insulin content) in response to hyperglycemic stimulus, as determined by
insulin immunoassay. ZnT8-depleted cells also showed fewer dense-core vesicles via electron microscopy. These data
indicate that reduced ZnT8 expression in cultured pancreatic beta cells gives rise to a reduced insulin response to
hyperglycemia. In addition, although we provide no direct evidence, these data suggest that an SLC30A8 expression-level
polymorphism could affect insulin secretion and the glycemic response in vivo.
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Introduction
An understanding of the relationship between zinc and diabetes
has evolved over decades. In insulin-containing vesicles of the
pancreatic beta cells, crystalline insulin is packaged with zinc
(reviewed in: [1]); in commercial preparations, insulin is
crystallized with zinc to slow absorption and onset of action
following subcutaneous administration. Perturbations in zinc
homeostasis disrupt carbohydrate metabolism; however, the
inverse relationship is also true: diabetes and hyperglycemia alter
zinc balance, promoting hypozincemia and hyperzincuria (re-
viewed in: [2]).
Interest in the role of zinc in the pathogenesis of diabetes was re-
ignited with the discovery, in five independent human genome-
wide association studies, of an association between type 2 diabetes
and a genetic polymorphism in the SLC30A8 gene [3–7]. This
gene codes for a newly described zinc transport protein, ZnT8 [8];
the minor allele of the single-nucleotide polymorphism
(rs13266634) introduces a non-conservative substitution (i.e.,
Arg-to-Trp) in amino acid 325. This polymorphism was
subsequently shown to be associated with the presence of altered
glucose homeostasis, pancreatic beta-cell dysfunction, or overt type
2 diabetes in many [9–14] but not all [15,16] study populations. In
addition to its putative role in type 2 diabetes, ZnT8 may also
serve as an autoantigen in type 1 diabetes [17].
Chimienti and co-workers originally described ZnT8 (the
product of the SLC30A8 gene) as a pancreatic islet-expressed
[8,18] protein belonging to the ZnT family of intracellular zinc
transport proteins. ZnT8 co-localized with insulin-containing
secretory vesicles in cultured rat INS-1 cells [8], a pancreatic beta
cell line derived from a rat insulinoma [19], and in human islet
cells [18]. HeLa cells heterologously expressing the transporter
exhibited increased zinc uptake in the presence of excess
extracellular zinc [8], as measured by the cell-permeant fluores-
cent zinc indicator dye, zinquin [20].
We show here that shRNA-mediated downregulation of ZnT8 in
rat INS-1 insulinoma cells reduces uptake of exogenous zinc, as
evidenced by zinquin fluorescence. The ZnT8-downregulated cells
showed reduced insulin content and decreased insulin secretion in
response to hyperglycemic stimulus, as determined by insulin
immunoassay. ZnT8-depleted cells also showed fewer dense-core
vesicles via electron microscopy. Many genetic polymorphisms
influence phenotype by altering the level of expression of their
respective proteins; some authorities feel that these expression-level
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5679polymorphisms are more significant – on a population-wide basis –
than are polymorphisms that directly impact protein structure or
function [21–29]. Although it is unclear what role – if any – the
diabetes-associated SLC30A8 polymorphism plays in aberrant
glucose homeostasis, our data suggest that a polymorphism
impacting only ZnT8 expression level might be sufficient to alter
beta-cell function and glucose metabolism in vivo.
Methods
Downregulation of ZnT8 in INS-1 cells using shRNA
stable transfection
Parental INS-1 cells were maintained in RPMI medium (which
includes no added zinc) supplemented with 10% fetal bovine serum,
sodium pyruvate (1 mM), HEPES (10 mM), and beta-mercaptoeth-
anol(50 uM).CellswerestablytransfectedwithpRSvector(Origene
# TR20003; cell line Vec-shRNA), pRS-shGFP (Origene #
TR30003; encoding non-effective 29-mer shGFP cassette as a
negative control; cell line GFP-shRNA), or with a combination of
specific ZnT8-directed 29-mer oligos (ZnT8-shRNA; see Table 1).
These 29-mers were incorporated in the forward and in the reverse
orientation, separated by a TCAAGAG loop, in the vector pRS
shRNA by the manufacturer to generate four pRS-based gene-
specific rat ZnT8 shRNA expression vectors (HuSH; Origene). All
were independently tested for their ability to down-regulate ZnT8
expression. The two most effective vectors (ZnT8-3 and ZnT8-4)
were then transfected in combination under puromycin selection
(2 mg/ml)to generatea pooled stable cellline,andwerecomparedto
INS-1 cells stably transfected (in parallel) with empty shRNA vector
or with GFP-directed shRNA. This procedure was repeated two
more times such that three complete and independent sets of Vec-
shRNA and ZnT8-shRNA stable transfectants were produced and
analyzed. The phenotype of these cell lines remained stable for
months in continuous culture; nonetheless, frozen stocks were
routinely thawed to ensure consistency throughout. Grossly,
morphology (via light microscopy) and growth properties of the
disparate cell lines were indistinguishable. We were unable to
demonstrate ZnT8 expression at the protein level using a
commercially available reagent (RZ8 anti-rat ZnT8 polyclonal
antibody; Mellitech, Grenoble, France). Although this reagent was
used successfully by other investigators (e.g., [8,18]), in our hands,
specific signal corresponding to the appropriate molecular mass
could not be discerned via immunoblotting in wild-type INS-1 cells
or in protein lysates prepared from rat pancreatic tissue (data not
shown).
Real-time PCR
Total cellular RNA was isolated from stable transfectants using
TriZol reagent (Invitrogen) in accordance with the manufacturer’s
directions. Total RNA (5 mg) was used to generate cDNA with the
SuperScript III First-Strand Synthesis System (Invitrogen); prod-
uct (3 ml) was amplified with TaqMan Universal PCR Master Mix
(Applied Biosystems) on a StepOne Plus platform (Applied
Biosystems). Rat-specific probe sets were obtained from ABI as
follows: ZnT8, XM_235269-sp13 (custom); ZnT4,
Rn00597094_m1 (ready-made); ZnT5, Rn01493874_m1 (cus-
tom); calcium channel, voltage-dependent, L-type, alpha 1C
subunit, Rn00709287_m1 (CACNA1C, ready-made); and calcium
channel, voltage-dependent, L-type, alpha 1D subunit,
Rn00568820_m1 (CACNA1D, ready-made). Comparisons were
made using the DDCt method [30] where a probe set directed
against rat 18S RNA and run in parallel served as an internal
control for each RNA. Assays were not multiplexed; all probe sets
were FAM-based. Although Ct can not be directly compared
across multiple probe sets (in contrast to data utilizing a single
probe set), the average Ct for the various probe sets (in Vec-
shRNA transfectants) was as follows: ZnT8, 21.7; ZnT4, 24.5;
ZnT5, 25.2; CACNA1C, 26.3; CACNA1D, 31.8; 18S, 8.0 (data
set used for figures).
Zinquin fluorescence and image analysis
For zinquin staining, INS-1 cells were passaged in complete
medium with 10% Chelex-treated FBS (e.g., [31]) on day 0. On
day 1, cells were treated for 3 h with control (zinc-free) medium, or
medium supplemented with 75 mM ZnCl2 or NiCl2. Cells were
then washed63, incubated for 30 min in HBSS in the presence of
zinquin (5 mM, unless otherwise indicated), and washed63 with
HBSS [8]. The plate was then read immediately in a FlexStationII
at emission wavelength 490 nm in the presence of excitation at
370 nm with an auto-cutoff set at 475 nm and photomultiplier
(PMT) gain set to HIGH. Raw fluorimetric data (e.g., as in figures)
are the averaged instrument readings for the indicated number of
replicate wells. Owing to their highly reproducible nature, these
data were not normalized. Background was taken to be the
fluorimetric reading in the absence of zinquin indicator dye (e.g.,
the white bars in figures; ,60,000 units). The FlexStation II
instrument was programmed to read each microplate well in six
separate regions and average them prior to reporting a value for
each well. These parameters and photomultiplier gain were kept
constant throughout all experiments.
For live-cell imaging, cells were grown in multiwell plates, and
treated with Zn
2+ or Ni
2+ and then loaded with zinquin as
described above. After the final wash, cells were returned to HBSS
and observed under epifluorescence conditions in a Leica DMIRB
inverted microscope with a Xenon-based Lambda LS light source,
with emission monitored at 510 nm in the presence of excitation at
380 nm. Monochrome images were recorded with a Hamamatsu
ORCA-ER charge-coupled device digital camera using OpenLab
Table 1. Effect of ZnT8-directed and irrelevant shRNA constructs upon ZnT8 expression in INS-1 cells.
Name 29-mer Target Sequence 29-mer ID ZnT8/Vector
vector N/A TR20003 1.00
GFP TR30003 1.04
ZnT8-1 ATGAGTCCAAGTGATCATCCAAGAAGACC TI100047 1.87
ZnT8-2 CTGCTACCATGGAGTTTCTTGAGAGGACT TI100048 1.20
ZnT8-3 TGTGAGCGCCTCTTGTATCCTGATTACCA TI100049 0.63
ZnT8-4 AGTGAACCAAGTGATTCTCTCTGTTCATG TI100050 0.54
doi:10.1371/journal.pone.0005679.t001
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direct comparison between conditions (e.g., zinc-treated vs. nickel-
treated), all imaging parameters (i.e., gain, binning, and exposure
duration) were kept constant. Image analysis was done strictly in
parallel: phase contrast images 2A and 2C were combined into a
single .tiff file prior to image processing; and epifluorescence
images B and D were combined into a single .tiff file prior to image
processing. In each of these combined image files, minor
adjustment in brightness were made using PhotoShop. For the
combined epifluorescence image represented by panels B and D,
contrast was enhanced such that input maximum per pixel was
reduced from 255 to 175 for clarity and to more faithfully
reproduce on the printed page the image viewed through the
eyepiece.
Insulin content and secretion
INS-1 cell insulin secretion and insulin content were measured
via enzyme-linked immunosorbent assay directed against rat
insulin (ALPCO Diagnostics; Insulin (Rat) High Range EIA).
INS-1 cells were passaged on day 0 at a density of 1610
6 cells/well
into 6-well plates in complete medium (containing 11.1 mM
glucose). On day 1, medium was changed to fresh medium with
3 mM glucose6,16 h (i.e., overnight). On day 2, cells were
washed once with HBSS (NaCl 114; NaHCO3 25.5; KCl 4.7;
MgCl2 1; KH2PO4 1.2; MgSO4 1.16; HEPES 20; CaCl2 2.5; [all
in mM]) supplemented with 3 mM glucose and 0.2% freshly-
prepared BSA (‘‘HBSS Plus’’). Cells were then incubated for 2 h in
fresh HBSS Plus, supplemented with glucose (to a final
concentration of 6 or 12 mM, as indicated) or KCl (to a final
concentration of 30 mM). After the 2-h incubation, supernatant
was collected and stored at 220 C overnight, centrifuged to
remove any debris, and then used for the secreted insulin assay.
Acidified ethanol (1 ml; 75% ethanol plus 1.5% HCl) was added to
monolayers in wells and cells were incubated overnight at 220 C.
On day 3, these acidified ethanol extracts were collected,
centrifuged to remove any debris, and used for the intracellular
insulin assay. Total insulin (in ng/ml) was calculated as secreted
insulin+intracellular insulin, and percent secreted insulin was
defined as (100*(secreted insulin/total insulin)). We used this more
specific strategy, rather than normalizing to total cellular protein,
because the insulin content differed among the cell lines; we
reasoned that this expression of secreted insulin as a fraction of
total cellular insulin content, as other groups have done (e.g.,
[32,33]) would be the most conservative approach in this instance.
Because both intracellular and secreted insulin would need to be
normalized to total cellular protein, were this alternative approach
to be adopted (i.e., normalization to total cellular protein), the
quotient would be identical to the numbers we report. Of note,
total protein content per well was equivalent in the VEC-shRNA
and ZnT8-shRNA cell lines (see Results). Were we to have
expressed insulin secretion on a ‘‘per cell’’ or ‘‘per mg total
protein’’ basis, then the consequence of ZnT8 downregulation vis-
a `-vis insulin secretion would have been more pronounced;
however, our normalization to total insulin content (rather than
protein content) permitted the VEC-shRNA and ZnT8-shRNA
bars to be roughly equivalent under control conditions (3 mM
glucose) in figures. The immunoassay was then carried out in
accordance with the manufacturer’s directions (ALPCO 80-
INSRTH-E01). Absorbance was read at 450 nm in a microtiter
plate reader (Molecular Devices). Where indicated, protein
concentration was measured using the DC Protein Assay (BioRad)
according to the manufacturer’s directions (Standard Assay
Protocol).
Electron microscopy
For electron microscopy, cells were released from the plate with
trypsin, quenched with 10% FBS-containing medium, and gently
pelleted in a microcentrifuge tube at 1000 g. The supernatant was
removed and replaced with fixative (2.5% glutaraldehyde/0.5%
paraformaldehyde/0.1% picric acid in HEPES buffer, pH 7.3)
and the cells were fixed overnight. The fixative solution was
removed, the pellet was washed in 0.1 M HEPES buffer (pH 7.3)
twice for 5 minutes each, and the buffer was removed and
replaced with a solution containing 1% osmium/1.5% potassium
ferricyanide and incubated at room temperature in the dark for
30 minutes. The osmium-containing solution was removed and
the pellet was washed 5 times in de-ionized water. The pellet was
then incubated for 30 minutes at room temperature in aqueous
0.5% uranyl acetate. The pellet was dehydrated in a series of
increasing alcohols and cleared with propylene oxide. The pellet
was then embedded in epoxy resin and cured overnight at 55 C.
Thin sections (80 nm) of the pellet were cut on a Leica Ultracut
ultramicrotome using a Diatome diamond knife. The sections
were placed on 200 mesh nickel coated grids and counterstained
with uranyl acetate and lead citrate. Digital images through the
meridian of individual cells (such that nucleoli were visible within
the nucleus) were randomly taken throughout the section by a
digital camera (AMT, Danvers, MA); this approach allowed for
consistency of images taken between treatment groups. The area
of the cells was determined using Image-Pro Plus software (Version
3.01, Media Cybernetics, Silver Springs, MD). Dense-core vesicles
were identified based upon morphology (appropriately-sized
vesicular structure with electron-dense core surrounded by halo
of lucency) and were counted by hand by an individual blinded to
treatment group. The density of dense-core vesicles/mm
2 of cell
cross-sectional area was calculated.
Results
shRNA-mediated knockdown of ZnT8 in INS-1 cells
We adopted an shRNA approach to knockdown ZnT8 in INS-
1 cells; cells were stably transfected with vectors coding for
shRNA constructs (HuSH 29mers; OriGene, Rockville, MD).
We initially screened a panel of four shRNAs (see Table 1). Two
of these shRNAs (3 and 4) resulted in decreased expression of
ZnT8 upon stable transfection in INS-1 cells (36% and 44%
decrease in mRNA expression, respectively; n=1). Thereafter,
cells were transfected with a combination of vectors 3 and 4 to
maximize effectiveness. The first set of stable transfectants was
created by transfecting INS-1 cells with vectors 3 and 4 (in
combination), or with the empty control plasmid. We adopted a
pooled stable transfectant strategy as we have used previously to
minimize the effect of integration site bias; however, because of
potential selection bias in pooled stable transfectants, this entire
stable transfection procedure was independently repeated twice
m o r e .I na l l ,t h r e ec o m p l e t esets of stable transfectants were
generated and analyzed. Transfection with the combination of
two ZnT8-directed shRNAs decreased ZnT8 mRNA expression
by an average of 9262% (p,0.0001; Figure 1; panel A).
Reduction in expression was 88%, 93%, and 94% in the first,
second, and third sets of stable transfectants, respectively. Of
note, stable transfection of INS-1 cells with an irrelevant shRNA
(directed against GFP) in a total of three separate transfectants
exhibited no effect upon ZnT8 mRNA abundance (1.0860.17,
relative to Control; data not shown). As additional controls to
assess for specificity of ZnT8 downregulation, the effect of ZnT8-
directed shRNA upon abundance of other beta cell-expressed
zinc transport proteins [34–36] and upon subunits comprising
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time PCR. Neither ZnT4 nor ZnT5 were down-regulated by the
ZnT8-directed shRNA; similarly, the products of the CACNA1C
and CACNA1D genes (coding for the a-1C and a-1D subunits of
the beta cell-expressed L-type voltage-gated calcium channel,
respectively) were not down-regulated by the treatment (Figure 1;
panel B). There is at present no satisfactory antibody for
detecting ZnT8 immunoreactivity. We tested one commercially
available reagent; however, we were unable to detect ZnT8
expression in wild-type INS-1 cells or in lysates from pancreas
(see Methods). Because we were unable to quantify the effect of
our shRNA approach upon ZnT8 protein abundance, we
resorted to a functional assay (see below).
Zinquin as a reporter for intracellular zinc content
Chimienti et al [8] and others have used the zinc-sensitive
fluorescent dye, zinquin, to qualitatively assess changes in
intracellular zinc concentration. We sought to test the feasibility
of this method in the present context using fluorescent imaging of
live cells in culture. INS-1 cells were loaded with zinquin ethyl
ester (5 mM630 min), exposed to either supplemental zinc or
nickel as described above, and imaged under excitation at 380 nm
and emission at 510 nm. There was negligible staining evident
under control conditions (i.e., in the presence of only nominal
levels of zinc; data not shown). There was robust staining in
response to 3-h exposure of cells to supplemental zinc (75 mM;
Figure 2; panel B), but negligible staining in response to 3-h
exposure of cells to supplemental nickel (75 mM: Figure 2; panel
D). Phase contrast views of the identical fields demonstrate intact
cell morphology under both circumstances (Figure 2; panel A, C).
The identical gain and exposure duration were used for the pair of
A and C, and for the pair of B and D; post-processing of both
image pairs was done strictly in parallel (see Methods). These data
demonstrated the inhomogeneous staining characteristic of this
assay (e.g., [8]).
ZnT8-downregulated cells exhibit less zinquin-
dependent fluorescence in the presence of exogenous
zinc
The zinquin assay of intracellular zinc concentration was
adapted for use in a medium-throughput microtiter-plate based
assay. Untransfected INS-1 cells were treated with control medium
or zinc-supplemented medium (+75 mM zinc sulfate) for three
hours, and then sham-treated or loaded with varying concentra-
tions of the zinc-sensitive dye, zinquin ethyl ester (5–
25 mM630 min). In the absence of zinquin, there was no
difference in fluorescence (emission at 490 nm in response to
excitation at 370 nm); however, the zinc-treated INS-1 cells
exhibited more robust zinquin fluorescence than control-treated
cells, and the effect was more pronounced at higher zinquin
concentrations (Figure 3; panel A). Of note, the non-specific signal
in the absence of zinquin dye – attributable to cell autofluores-
cence – serves as an internal control for cell plating density.
We next sought to compare zinquin fluorescence in vector-
transfected INS-1 cells and in the ZnT8-downregulated INS-1
cells. In the vector-transfected (negative control) cells, zinquin
fluorescence was much higher following exogenous zinc treatment
(75 mM63 h) than vehicle treatment (Figure 3; panel B). Cells
were treated with an equivalent concentration of nickel ions as an
additional negative control; there was only a very modest effect of
exogenous nickel upon zinquin fluorescence. These data were
consistent with the zinquin-dependent fluorescent signal reflecting
intracellular zinc concentration. In ZnT8-downregulated INS-1
cells (ZnT8-shRNA), zinquin fluorescence was reduced relative to
vector-transfected INS-1 cells. Even in the absence of supplemen-
tal zinc, zinquin-dependent fluorescence (i.e., fluorescence in the
presence of zinquin, minus background fluorescence in the
absence of zinquin) was reduced by 75% in the knock-down cells;
although not reaching statistical significance (p=0.16), such a
phenomenon could reflect intracellular zinc retained from
exposure prior to the 3-h incubation period. Following loading
with 75 mM zinc, zinquin-dependent fluorescence was reduced by
56% in the ZnT8-down-regulated cells relative to the vector-
transfected cells (p=0.03). This suggested reduced intracellular
zinc concentration in the ZnT8-downregulated cells. Of note, the
background fluorescence in the absence of zinquin dye, reflective
of cell plating density, was nearly identical in both groups (i.e.,
Figure 1. Effect of ZnT8-specific shRNA upon ZnT8 mRNA level
in cultured INS-1 cells. A. Relative ZnT8 mRNA abundance as
determined via real-time PCR in INS-1 cells were stably transfected with
shRNA directed against rat ZnT8 (ZnT8-shRNA) or with shRNA vector
alone (VEC-shRNA). Of note, the ZnT8-directed shRNA was comprised of
two separate inserts (ZnT8-3 and ZnT8-4; see Table 1) cloned
independently into expression vector and applied in combination. A.
Stable cell lines were generated with these vectors on three separate
occasions and the results from these three separate experiments are
shown here (n=3, with one determination per experiment). * denotes
p,0.0001 relative to VEC-shRNA. B. Specificity of ZnT8 downregulation.
RNA prepared from cells treated as in A were assessed via real-time PCR
(n=3) for the presence of ZnT8, for the presence of additional beta cell-
expressed ZnT family members (ZnT4 and ZnT5), and for the presence
of the alpha-1C and alpha-1D subunits of the beta cell-expressed L-type
voltage-gated calcium channel (i.e., CACNA1C and CACNA1D gene
products). For each mRNA, expression data were normalized to VEC-
shRNA cells.
doi:10.1371/journal.pone.0005679.g001
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achieve statistical significance); this was unlikely to be a factor in
the observed difference in zinc fluorescence. In aggregate, these
data indicated that chronic ZnT8 downregulation influences
intracellular zinc concentration and support an effect of ZnT8-
directed shRNA upon ZnT8 protein expression. ZnT8 overex-
pression enhanced zinquin fluorescence [8,18]; ZnT8-directed
shRNA reduces it.
ZnT8 knockdown cells exhibit less insulin
immunoreactivity and reduced insulin secretion in
response to glucose
With this functional characterization in hand, we tested the
effect of ZnT8 downregulation upon insulin secretion. ZnT8
downregulation reduced total intracellular insulin content by
53.5% relative to vector-transfected cells (Figure 4; panel A). Of
note, there was no difference in total protein content per well
between the vector-transfected and ZnT8-downregulated cells
(5416102 vs. 610696 mg/well, respectively; p=0.2 for corre-
lated samples), therefore this could not have accounted for the
observed differences in insulin content. We next assessed insulin
secretion in response to a glucose challenge (either 6 or 12 mM
glucose supplementation, corresponding to 108 and 216 mg/dl,
respectively), and in response to membrane depolarization with
potassium chloride (30 mM). In vector-transfected cells, insulin
secretion (expressed as percent of total insulin) was markedly
increased by glucose treatment or KCl-mediated depolarization
(Figure 4; panel B). Insulin secretion at baseline (Control) and in
response to KCl-mediated depolarization was equivalent in
vector-transfected and ZnT8-shRNA-transfected cell lines
(Figure 4; panel B). Insulin secretion in response to 6 mM
glucose was reduced by 45% in the ZnT8-downregulated cells
(p=0.04). The response to a higher glucose challenge (12 mM)
was similarly decreased by 43% in the ZnT8-downregulated
cells; however, this relationship was only suggestive and did not
achieve statistical significance (p=0.09). Although pooled data
from all three sets of stable transfectants are shown in Figure 4
(panel B; where each set equals one ‘‘n’’), this same pattern was
evident in each of the three independent sets of stable
transfectants (data not shown).
ZnT8 down-regulation results in fewer dense core
vesicles per unit cross-sectional area
From an ultrastructural standpoint, dense-core vesicles are the
site of insulin storage in pancreatic beta cells; elevated levels of
circulating glucose cause the vesicles to fuse with the plasma
membrane and secrete the insulin-rich contents (reviewed in: [1]).
Therefore, we next tested for the presence of these vesicles via
electron microscopy in the INS-1 stable transfectants. There were
markedly fewer dense-core vesicles in the ZnT8-shRNA transfec-
tants (0.8 vesicles vs. 3.2 vesicles per square micron of cell cross-
sectional area; p,0.01; Figure 5; panel A). Of note, there were no
gross differences in vesicle size, morphology, or subcellular
distribution between groups (e.g., Figure 5; panels B,C).
Figure 2. Zinquin staining in zinc- and nickel-treated INS-1 cell monolayers. A, C. Phase contrast view of untransfected INS-1 cells (original
magnification: 2006) loaded with zinquin ethyl ester and treated for 3 h with zinc (75 mM ZnCl2; A) or nickel (75 mM NiCl2; C) and then loaded with
zinquin as described in Methods. B, D. Epifluorescence views of the same fields depicted in A and C with emission monitored at 510 nm in the
presence of excitation at 380 nm. Image pairs (A and C; B and D) were obtained using identical gain, binning, and exposure duration. Image pairs
were combined into a single file (e.g., A+C, and B+D) prior to minor image processing in PhotoShop (Adobe) such that brightness and contrast were
adjusted in parallel for the pair (see Methods for details). There is a lack of illumination in the lower right corner of panel B (and, imperceptibly, in
panel D) as a consequence of the slight eccentricity of the epifluorescent illumination with respect to the brightfield illumination; viable cells were
present in this region as evidenced in panel A but did not receive excitation.
doi:10.1371/journal.pone.0005679.g002
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These data indicate that down-regulation of ZnT8 expression in
a cultured pancreatic beta-cell line results in reduced zinc
fluorescence, insulin content, glucose-inducible insulin secretion,
and dense-core vesicle number.
ZnT8 was identified after a search of a human expressed
sequence tag database for motifs exhibiting similarity to any
known human zinc transporter of the ZnT family [8]. ZnT8
expression at the mRNA level is restricted to pancreatic islets
[8,18], and a ZnT8-GFP fusion protein showed co-localization
with insulin in INS-1 secretory vesicles [8]. Experiments based
upon zinquin staining suggested that heterologous expression of
ZnT8 in HeLa cells could confer enhanced cellular uptake of
exogenous zinc [8]. Although no prior studies have examined the
effect of ZnT8 downregulation, Chimienti and colleagues
overexpressed ZnT8 in INS-1 cells [18]. In these studies,
transfectants overexpressing the zinc transporter showed a marked
increase in insulin secretion in response to hyperglycemic
challenge. We hypothesized that downregulation of ZnT8 would
decrease glucose responsiveness vis-a `-vis insulin secretion; this
effect was observed in the present studies.
The present data indicate that a reduction in the expression
level of ZnT8 is associated with a marked decrease in intracellular
insulin content in cultured rat insulinoma cells, and a reduction in
the glucose-stimulated secretion of insulin. The reduction in this
secretion – in absolute terms – is even greater than that implied
by Figure 4; because ZnT8-downregulated cells express half as
much insulin – on a ‘‘per mg of cell protein’’ basis – the absolute
reduction in insulin secretion is even more dramatic. Nonetheless,
secreted insulin is reduced even when assessed by the very
conservative measure reported in Figure 4. Our findings, along
with those of Chimienti et al wherein overexpression of ZnT8
resulted in enhanced zinquin fluorescence and insulin secretion
[8,18], suggest a zinc-importing role for ZnT8; however,
abundant data for other members of the ZnT family have led
to the conclusion that ZnT proteins function primarily in zinc
efflux from cells, or in its sequestration in intracellular vesicles
(reviewed in: [37]). Whether this discrepancy reflects the unique
functional properties of ZnT8 or an incomplete understanding of
Figure 3. Effect of ZnT8 down-regulation upon intracellular zinc levels as assessed via zinquin fluorescence. In panel A, untransfected
INS-1 cells in 96-well microtiter plates were treated for 3 h with control (nominally zinc-free) medium and Chelex resin-treated fetal bovine serum
(10% vol:vol), or the identical medium/serum combination supplemented with zinc (75 mM zinc sulfate). Cells were then washed, incubated for
30 min in HBSS with the indicated concentration of zinquin ester, and washed again. Each bar represents mean6SEM of twelve replicates; depicted
figure is representative of two separate experiments. Fluorescence was measured with excitation at 370 nm and emission at 490 nm. Exogenous zinc
markedly increases zinquin fluorescence at all tested concentrations of the dye. In panel B, this microtiter plate-based zinquin fluorescence assay was
applied to stable cells expressing VEC-shRNA or ZnT8-shRNA, following incubation with control medium (Zn 0) or with medium supplemented with
75 mMZ n( Zn 75 mM) or Ni (negative control; Ni 75 mM). Fluorescence under control conditions in the absence of zinquin is also shown (No Dye).
Each bar represents mean6SEM of three separate experiments (i.e., three sets of stable transfectants, each with twelve replicates). * denotes p,0.05
relative to the same experimental condition in VEC-shRNA stable transfectants. Down-regulation of ZnT8 resulted in less zinquin fluorescence in the
absence (Zn 0) and presence (Zn 75 mM) of supplemental zinc; there was no effect upon fluorescence in the presence of nickel (Ni 75 mM) or in the
absence of dye (No Dye).
doi:10.1371/journal.pone.0005679.g003
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investigation.
An understanding of the role of ZnT8 in the pathogenesis of
diabetes is evolving rapidly. Shortly after the initial cloning of
ZnT8, a polymorphism in the SLC30A8 gene giving rise to a
non-conservative amino acid substitution in the ZnT8 trans-
porter was shown to be strongly associated with type 2 diabetes
[3]; this association was subsequently replicated in numerous
(e.g., [4–7]) but not all [38] genome-wide association analyses.
The present data, in conjunction with the prior population-based
studies suggesting a role for the diabetes-associated SLC30A8
polymorphism in insulin secretion or action, raise the question of
whether SLC30A8 risk alleles directly impact ZnT8 expression
level in vivo. As our current understanding evolves, such
expression-level polymorphisms may supplant functional poly-
morphisms (i.e., those giving rise to loss or gain of function) as
the primary drivers of inter-individual phenotypic variability
[21–29]. Because the expression pattern of SLC30A8 is so
anatomically restricted, it will be challenging to assess for such
variability in mRNA expression in vivo; pancreatic biopsies will
likely not be undertaken for this purpose, and post-mortem
examination may be confounded by the effects of years of
diabetes. In addition to pancreas, ZnT8 was recently shown to
be expressed in adipose tissue [39], which may prove more
amenable to in vivo investigation. Although little is known about
the mechanism through which the rs13266634 polymorphism in
the SLC30A8 gene confers susceptibility to diabetes, we speculate
that reduced endogenous expression of the ZnT8 transporter
constitutes one possible mechanism. However, irrespective of the
mechanism of action of this one polymorphism, the present data
suggest that expression-level polymorphisms have the potential
to impact glucose homeostasis.
A number of caveats apply to the interpretion of the present
data. First, although we reproducibly decreased ZnT8 expression
at the mRNA level, we could not assess whether there had been a
corresponding reduction in ZnT8 expression at the protein level.
We infer downregulation of ZnT8 expression at the protein level
based upon the specific inhibition in zinc-dependent zinquin
fluorescence in the ZnT8-shRNA transfectants (e.g., Figure 3) – a
phenomenon linked to ZnT8 abundance [18]. We infer specificity
vis-a `-vis ZnT8 because of the lack of effect upon abundance of
other closely related beta cell-expressed ZnT family members
(Figure 1B).
Second, measuring intracellular zinc can be problematic. The
widely validated zinc-sensitive fluorophore, zinquin [8,20,40], was
used in the present studies. We incorporated a number of
important controls in support of our conclusion that intracellular
zinc is reduced in INS-1 cells in response to ZnT8 downregulation.
For example, zinquin fluorescence increased with zinquin
concentration in a fashion steeply dependent upon supplemental
zinc (Figure 3A). The issues of potential zinc toxicity and of
zinquin specificity were addressed by the inclusion of the irrelevant
metal ion, Ni
2+, which failed to influence zinquin fluorescence
(Figure 3B). In addition, extraneous sources of zinc were
eliminated by using nominally zinc-free medium and by treating
fetal bovine serum with the heavy metal-chelating resin Chelex as
previously described (e.g., [31]).
Third, the effect of ZnT8 downregulation was specific to
glucose-inducible insulin secretion and did not impact KCl-
inducible insulin secretion. It is possible that the stimulus
afforded by KCl depolarization, resulting in maximal recruit-
ment of insulin secretory vesicles, was less susceptible to
modulation; alternatively, the nature of the two stimuli – in
contrast to the magnitude of the stimuli – may explain the
difference. For example, ZnT8 may participate in the insulin
secretory pathway upstream of membrane depolarization;
however, there are no data to support this speculation at
present. It is also important to note that the absolute amount of
insulin secreted in response to both glucose and KCl was
markedly less in the ZnT8-downregulated cells; however, the
reduction in the insulin response to glucose was disproportion-
ately low, relative to the reduction in total cellular insulin (i.e.,
data were expressed as percent of total cellular insulin and the
ZnT8-downregulated cells expressed only approximately half as
much insulin). In related fashion, KCl depolarization may be
Figure 4. Effect of ZnT8 down-regulation upon intracellular
insulin content and stimulated release of insulin. A. Intracellular
insulin content (in ng/ml, and expressed relative to control) in INS-1
cells stably transfected with shRNA directed against vector (VEC-shRNA)
or against rat ZnT8 (ZnT8-shRNA), as quantitated via immunoassay
directed against rat insulin. Insulin content in the ZnT8-downregulated
cells was 53.5% less (mean of data from three independently generated
stable transfectants (n=3), where each ‘‘n’’ represents 2–3 separate
experiments per transfected cell line. Of note, total protein content per
well for the VEC-shRNA and ZnT8-shRNA cells was equivalent (see
Results). B. Insulin secretion (expressed as percent of total, i.e.,
100*[secreted insulin/(intracellular insulin+secreted insulin)]) in VEC-
shRNA and ZnT8-shRNA stable transfectants under control conditions,
and in response to treatment with exogenous glucose (6 mM or
12 mM) or KCl (30 mM). ‘‘Control’’ condition denotes 3 mM glucose.
Data are expressed as the mean6SEM for three independent stably
transfected cell lines, where data for each transfection with a given cell
line represents the mean of 3–5 individual experiments with an ‘‘n’’ of
two replicates per experiment. * denotes p,0.05 with respect to
vector-treated cells. The effect of glucose 6 mM achieved statistical
significance (p=0.04), whereas that of glucose 12 mM and KCl were
suggestive of an effect (i.e., p=0.09 and p=0.09, respectively).
doi:10.1371/journal.pone.0005679.g004
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challenge. We saw substantial inter-assay variability and in
some individual experiments, the effect of KCl exceeded that of
glucose; however, the aggregated data showed similar responses
in the control (vec-shRNA) stable transfectants.
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